Table 4.
Migration assay.
| Group | MDA-MB-231 | MCF-7 | BT-474 | SKBR-3 | MCF-10A |
|---|---|---|---|---|---|
| LPA 0.1 μM | + | + | Ø | + | Ø |
| LPA 1.0 μM |
++ p = 0.01 (24 h) p = 0.03 (48 h) |
++ p = 0.03 (72 h) |
Ø |
++ p = 0.02 (72 h) |
Ø |
|
LPA 0.1 μM + Ki16425 2 μM |
– | Ø | Ø | Ø | Ø |
|
LPA 1.0 μM + Ki16425 2 μM |
– | Ø | Ø | Ø | Ø |
|
LPA 0.1 μM + Ki16425 20 μM |
– – p = 0.01 (24 h) p = 0.02 (48 h) |
– | Ø | – | Ø |
|
LPA 1.0 μM + Ki16425 20 μM |
– – p = 0.01 (24 h) p = 0.01 (48 h) |
– | Ø | – | Ø |
Effect of lysophosphatidic acid (LPA) 18:1 and the LPA receptor 1, 3 (and 2) inhibitor Ki16425 on migration after 24 h, 48 h, and 72 h of different human breast (cancer) cell lines. n = 3 replicate experiments, a p-value ≤ 0.05 was considered significant (Kruskal–Wallis test and post-hoc Dunn’s test).
Ø: no effect; +: stimulatory trend; ++: statistically significant stimulation; –: inhibitory trend; – –: statistically significant inhibition. For LPA 0.1 μM and LPA 1.0 μM stimulation was compared to the control group; for LPA 0.1 μM/LPA 1.0 μM + Ki16425 2/20 μM inhibition was compared to the respective LPA group without Ki16425.